GCP
ONCE

GSA Capital Partners’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

GSA Capital Partners’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,200
Closed -$417K – 2027
2015
Q4 		$417K Buy
9,200
+4,182
+83% +$219K 0.02% 1271
2015
Q3 		$209K Sell
5,018
-4,806
-49% -$251K 0.01% 1559
2015
Q2 		$592K Buy
+9,824
New +$650K 0.02% 1241

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RS Investment Management
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

GSA Capital Partners's ONCE Position: Q1 2016 in Review

GSA Capital Partners sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2016, closing a stake of 9,200 shares — an estimated $417K sold.

GSA Capital Partners first reported a position in ONCE in Q2 2015 and held it in 3 quarters. The position peaked at $592K in Q2 2015. 105 funds tracked by Wall St. Rank hold ONCE as of Q1 2016.

  • GSA Capital Partners reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • GSA Capital Partners sold 9,200 Spark Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $417K.
  • GSA Capital Partners first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 3 quarters.
  • GSA Capital Partners's Spark Therapeutics, Inc. Common Stock position peaked at $592K in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2016.

Based on GSA Capital Partners's 13F filing for Q1 2016, filed 11 May 2016.